The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
This article was written by Dr Mary Gleeson from the Royal Marsden Hospital in London and Surrey and her co-authors from various centers around the UK, and was published in the British Journal of Haematology on 1st of August 2016. The article describes the data from a subgroup analysis that evaluated the outcomes of patients (n=50) with primary mediastinal B-cell lymphoma (PMBL), which is a distinct type of diffuse large B-cell lymphoma (DLBCL); treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) with or without radiotherapy (RT) within the randomized phase III UK NCRI R-CHOP-14 trial (six cycles of R-CHOP every 14 days plus 2 cycles of rituximab) versus the R-CHOP-21 trial (8 cycles of R-CHOP every 21 days). The primary endpoint of the study was to determine overall survival (OS) and the secondary endpoints were to evaluate progression free survival (PFS) and response rate. Response following chemotherapy with R-CHOP was evaluated by computer tomography (CT) scans of the thorax, abdomen and pelvis with or without neck.
Although it was the largest PMBL cohort treated by R-CHOP, the number of patients was small and therefore more robust studies need to be established that would have more significant multivariate analysis; however, the data demonstrated in this study does provide evidence of R-CHOP efficacy in the management of PMBL and provides the ground work for other clinical trials. Dose-intensity should also be considered in future trials for this specific subtype of DLBCL.
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median followup of 7.2 years the 5-year progression-free survival and overall survival was 79.8% and 83.8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.
References